158 related articles for article (PubMed ID: 2558611)
1. In vitro activity of amifloxacin against outer membrane mutants of the family Enterobacteriaceae and frequency of spontaneous resistance.
Watanabe M; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1989 Nov; 33(11):1837-40. PubMed ID: 2558611
[TBL] [Abstract][Full Text] [Related]
2. Activity of KB-5246 against outer membrane mutants of Escherichia coli and Salmonella typhimurium.
Kotera Y; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1990 Jul; 34(7):1323-5. PubMed ID: 2167038
[TBL] [Abstract][Full Text] [Related]
3. Fleroxacin resistance in Escherichia coli.
Chapman JS; Bertasso A; Georgopapadakou NH
Antimicrob Agents Chemother; 1989 Feb; 33(2):239-41. PubMed ID: 2541657
[TBL] [Abstract][Full Text] [Related]
4. In vitro antibacterial activities of tosufloxacin against and uptake of tosufloxacin by outer membrane mutants of Escherichia coli, Proteus mirabilis, and Salmonella typhimurium.
Mitsuyama J; Itoh Y; Takahata M; Okamoto S; Yasuda T
Antimicrob Agents Chemother; 1992 Sep; 36(9):2030-6. PubMed ID: 1329639
[TBL] [Abstract][Full Text] [Related]
5. Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424.
Pace J; Bertasso A; Georgopapadakou NH
Antimicrob Agents Chemother; 1991 May; 35(5):910-5. PubMed ID: 1649574
[TBL] [Abstract][Full Text] [Related]
6. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of amifloxacin and two of its metabolites.
Venezia RA; Prymas LA; Shayegani A; Yocum DM
Antimicrob Agents Chemother; 1989 May; 33(5):762-6. PubMed ID: 2751287
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of amifloxacin (WIN 49,375) compared with those of ciprofloxacin and ofloxacin.
Digranes A
Acta Pathol Microbiol Immunol Scand B; 1987 Feb; 95(1):29-32. PubMed ID: 3105246
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of Ro 23-6240, a new fluorinated 4-quinolone.
Stobberingh EE; Houben AW; van Boven CP
Chemotherapy; 1987; 33(3):197-203. PubMed ID: 3109817
[TBL] [Abstract][Full Text] [Related]
10. The Global Regulatory Cyclic AMP Receptor Protein (CRP) Controls Multifactorial Fluoroquinolone Susceptibility in Salmonella enterica Serovar Typhimurium.
Kary SC; Yoneda JRK; Olshefsky SC; Stewart LA; West SB; Cameron ADS
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874380
[TBL] [Abstract][Full Text] [Related]
11. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.
Alovero FL; Pan XS; Morris JE; Manzo RH; Fisher LM
Antimicrob Agents Chemother; 2000 Feb; 44(2):320-5. PubMed ID: 10639357
[TBL] [Abstract][Full Text] [Related]
12. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
[TBL] [Abstract][Full Text] [Related]
13. Amifloxacin activity against well-defined gentamicin-resistant, gram-negative bacteria.
John JF; Twitty JA
Antimicrob Agents Chemother; 1984 Nov; 26(5):781-4. PubMed ID: 6440481
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic characterization of quinolone-resistant mutants of Enterobacteriaceae selected from wild type, gyrA type and multiply-resistant (marA) type strains.
Piddock LJ; Hall MC; Walters RN
J Antimicrob Chemother; 1991 Aug; 28(2):185-98. PubMed ID: 1663926
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent.
Neu HC; Labthavikul P
Diagn Microbiol Infect Dis; 1985 Nov; 3(6):469-78. PubMed ID: 4064609
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field.
Giraud E; Brisabois A; Martel JL; Chaslus-Dancla E
Antimicrob Agents Chemother; 1999 Sep; 43(9):2131-7. PubMed ID: 10471553
[TBL] [Abstract][Full Text] [Related]
17. Sitafloxacin: antimicrobial activity against ciprofloxacin-selected laboratory mutants of Mycoplasma genitalium and inhibitory activity against its DNA gyrase and topoisomerase IV.
Deguchi T; Kikuchi M; Yasuda M; Ito S
J Infect Chemother; 2015 Jan; 21(1):74-5. PubMed ID: 25245990
[TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
Tankovic J; Bachoual R; Ouabdesselam S; Boudjadja A; Soussy CJ
J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
[TBL] [Abstract][Full Text] [Related]
19. Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients.
Piddock LJ; Griggs DJ; Hall MC; Jin YF
Antimicrob Agents Chemother; 1993 Apr; 37(4):662-6. PubMed ID: 8494360
[TBL] [Abstract][Full Text] [Related]
20. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
Pasquali F; Manfreda G
Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
